VRTX - Vertex Pharmaceuticals Incorporated

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $573.50 DETAILS

Stock News

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

Both of these ETFs look the part, but only one is truly the better buy for investors.

Oct 22, 2026 01:30 AM • fool.com

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.

Oct 20, 2026 02:51 PM • zacks.com

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates massive free cash flow while successfully navigating the loss of exclusivity for its top-selling drug. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into gene editing and pain management.

Oct 20, 2026 01:15 PM • fool.com

Vertex Appoints Daniel Brennan to its Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific's Executive Vice President, Chief Fi.

Oct 20, 2026 12:05 PM • businesswire.com

3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA

Banque Pictet and Cie SA trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 15.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,818 shares of the pharmaceutical company's stock after selling 3,678 shares during the period.

Oct 16, 2026 11:26 PM • defenseworld.net

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Oct 16, 2026 06:01 AM • zacks.com

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

Oct 15, 2026 03:00 PM • zacks.com

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.

Oct 15, 2026 06:41 AM • fool.com

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Moderna is leveraging its mRNA platform to expand beyond COVID-19 vaccines into RSV and oncology therapeutics. Vertex Pharmaceuticals maintains market dominance in cystic fibrosis while successfully diversifying into gene therapy and pain management.

Oct 13, 2026 04:17 AM • fool.com

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Oct 10, 2026 08:19 AM • fool.com

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.

Oct 09, 2026 02:51 PM • zacks.com

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib.

Oct 09, 2026 09:15 AM • businesswire.com

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast ca.

Oct 07, 2026 12:00 PM • businesswire.com

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Oct 05, 2026 06:01 AM • zacks.com

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Amgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market and is expanding into high-growth gene therapies.

Oct 04, 2026 06:14 AM • fool.com

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.

Oct 01, 2026 03:00 PM • zacks.com

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.

Oct 01, 2026 10:57 AM • fool.com

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

Sep 30, 2026 03:06 AM • etftrends.com

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks.

Sep 29, 2026 01:10 AM • fool.com

2 Healthcare Stocks That Just Delivered Great News for Investors

Vertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates. Both companies have robust businesses and strong medium-term prospects.

Sep 26, 2026 12:01 PM • fool.com